For patients receiving immune checkpoint inhibitors (ICIs), rheumatic immune-related adverse events (rh-irAEs) are usually moderate or severe, with more than one-third leading to permanent ICI discontinuation, according to a study published online Sept. 8 in ACR Open Rheumatology.